Fit Investment Ideas

I wrote last week about Africa Energy news announced at the Pareto conference. I also updated my valuation based on the information provided. Today, Sparebank produced a note on AEC. See the summary below: Africa Energy (Buy, tp NOK 4) – History repeats itself, ride on Gazania exploration well and 11B/12B gas price update keyContinue reading “SpareBank on Africa Energy – “…there should be plenty of weeks ahead with continues positive share price trend”.”

Garrett Soden delivered excellent performance at the Pareto Energy conference in Oslo yesterday. AEC is my top oil company position. I believe it has a potential to triple over the next 12 months. There is one big difference between AEC and other oil plays. There are many oil companies that have great portfolios and areContinue reading “Africa Energy – excellent update from Pareto conference – valuation impact assessment”

Redeye Tesearch just published new research note on Biovica. The research is available on Biovica website: Biovica: Fundamental support and an administrative delay When Biovica announced that the FDA was not yet ready to accept Biovica’s updated application, this triggered a severe negative overreaction despite no impact on fundamental support. Biovica announced the Novartis independentContinue reading “Redeye Research on Biovica: the unnoticed news supports Bull case of SEK 325.”

Quantafuel update from the Pareto conference today: CEO Terje Eleken: “… we are confident reaching the proof of concept before the year end…. I am extremely confident we will make it work” “we have worked on this for a long time, we have run tests Dr. Lach (deputy CEO): “Esbjerg plant on time, we areContinue reading “Quantafuel CEO at Pareto conference: “I am extremely confident we will make it work before the year end””

Last week NSKOG was put on Top Ideal list for Septermber by Pareto and SpareBank. Sparebank believes the Norske Skog share price should be three times higher. Yesterday, Carnegie joined the NSKOG bulls with doubling its price target. Carnegie brings another component into its valuation. NSKOG transformation into green products will increase the amount NSKOGContinue reading “Norske Skog: Carnegie almost doubles its price target”

Pareto issued a note on Monday, that the FDA delay has no material impact on the Biovica value, and the sale off is unjustified. Redye research also came up with the same conclusion. The research is available for free on Biovica website. Full report is below: Redeye Research: Biovica: The submission of the updated applicationContinue reading “Biovica: Redeye Research joins Pareto in declaring the sell off as a nervous overreaction without and support in changing fundamentals”

The selling was due to the Biovica s press release stating that FDA is in delay due to the Corona Virus work overload. I enclose Pareto Minutes of the call with the management published minutes ago. The minutes indicate, that there is no justification for the sell off. The Biovica value does not change whetherContinue reading “Biovica sell off – Minutes of the call with the management”

SpareBank and Pareto have in their Top Pick portfolio for September jointly just one stock – Norske Skog. Two days ago I wrote here about Pareto strategic portfolio for September. I enclose below SpareBank Top Pick summary. As mentioned above, there is just one stock that is in both Top Pick portfolios – Norske Skog.Continue reading “SpareBank joins Pareto by adding Norske Skog into Top Pick Portfolio for September”

Sparebank believes the Norske Skog share price should be three times higher. NSKOG is my favorite restructuring play. NSKOG has four levers for share price growth: it is very cheap vs its peers – see below Sparebank: “if valued in line with peers, we argue that a fair price is closer to NOK 100” itsContinue reading “Sparebank on Norske Skog – Newsprint prices up 15%-20%. Share priced did not move, yet”

ABG Sundal Collier just issued their update on Biovica. I include the full report below. Very bullish There are two major points in the research: During the quarter, the company has interacted with theFDA and undergone a Submission Issue Request (SIR) process . This isa routine way for the FDA to resolve or clarify minorContinue reading “ABG Sundal on Biovica: “Closing on the finish Line””